These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21822913)

  • 21. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Aapro MS; Grunberg SM; Manikhas GM; Olivares G; Suarez T; Tjulandin SA; Bertoli LF; Yunus F; Morrica B; Lordick F; Macciocchi A
    Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
    Alvarez O; Freeman A; Bedros A; Call SK; Volsch J; Kalbermatter O; Halverson J; Convy L; Cook L; Mick K
    J Pediatr Hematol Oncol; 1995 May; 17(2):145-50. PubMed ID: 7749764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R; Grunberg S; Franco-Gonzales E; Rubenstein E; Voisin D
    Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
    Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
    Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
    Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
    Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
    Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
    Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
    Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
    Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
    Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
    Abdel-Malek R; Abbas N; Shohdy KS; Ismail M; Fawzy R; Salem DS; Safwat E
    J Egypt Natl Canc Inst; 2017 Sep; 29(3):155-158. PubMed ID: 28844591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
    Cruz FM; de Iracema Gomes Cubero D; Taranto P; Lerner T; Lera AT; da Costa Miranda M; da Cunha Vieira M; de Souza Fêde AB; Schindler F; Carrasco MM; de Afonseca SO; Pinczowski H; del Giglio A
    Support Care Cancer; 2012 Mar; 20(3):601-6. PubMed ID: 21465325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
    Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
    J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
    Hesketh PJ; Sanz-Altamira P; Bushey J; Hesketh AM
    Support Care Cancer; 2012 May; 20(5):1043-7. PubMed ID: 21553313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
    Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
    Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
    Ng WL; Della-Fiorentina SA
    Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
    Thamlikitkul L; Srimuninnimit V; Akewanlop C; Ithimakin S; Techawathanawanna S; Korphaisarn K; Chantharasamee J; Danchaivijitr P; Soparattanapaisarn N
    Support Care Cancer; 2017 Feb; 25(2):459-464. PubMed ID: 27714530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.